Literature DB >> 12150987

G(q/11) is involved in insulin-stimulated inositol phosphoglycan putative mediator generation in rat liver membranes: co-localization of G(q/11) with the insulin receptor in membrane vesicles.

S Sleight1, B A Wilson, D B Heimark, J Larner.   

Abstract

Insulin signaling to generate inositol phosphoglycans (IPGs) was demonstrated to occur via the participation of the heterotrimeric G-proteins G(q/11). IPGs were measured as two specific inositol markers, myo-inositol and chiro-inositol after strong acid hydrolysis. Insulin and Pasteurella multocida toxin (PMT) generated both myo-inositol and chiro-inositol IPGs in a dose-dependent manner. PMT has been shown to activate G(q) specifically. Insulin action was abrogated by pre-treatment with anti G(q/11) antibody. Western blotting demonstrated the enrichment of both insulin receptor beta subunit and G(q/11) in the liver membrane vesicles. Vesicles also contained clathrin, caveolin PLC beta 1 and PLC Delta. Immunogold staining revealed the co-localization of both insulin receptor beta subunit and G(q/11) in an approximate stochiometric ratio of 1:3. No vesicles were detected with either component alone. The present and considerable published data provide strong evidence for insulin signaling both via a tyrosine kinase cascade mechanism and via heterotrimeric G-protein interactions.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12150987     DOI: 10.1016/s0006-291x(02)00701-5

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  8 in total

Review 1.  Pasteurella multocida toxin as a tool for studying Gq signal transduction.

Authors:  B A Wilson; M Ho
Journal:  Rev Physiol Biochem Pharmacol       Date:  2004-09-29       Impact factor: 5.545

Review 2.  D-chiro-inositol glycans in insulin signaling and insulin resistance.

Authors:  Joseph Larner; David L Brautigan; Michael O Thorner
Journal:  Mol Med       Date:  2010-08-27       Impact factor: 6.354

3.  Herbal constituent sequoyitol improves hyperglycemia and glucose intolerance by targeting hepatocytes, adipocytes, and β-cells.

Authors:  Hong Shen; Mengle Shao; Kae Won Cho; Suqing Wang; Zheng Chen; Liang Sheng; Ting Wang; Yong Liu; Liangyou Rui
Journal:  Am J Physiol Endocrinol Metab       Date:  2012-01-31       Impact factor: 4.310

4.  Uncoupling between insulin and release of a D-chiro-inositol-containing inositolphosphoglycan mediator of insulin action in obese women With polycystic ovary syndrome.

Authors:  Jean-Patrice Baillargeon; Maria J Iuorno; Teimuraz Apridonidze; John E Nestler
Journal:  Metab Syndr Relat Disord       Date:  2010-04       Impact factor: 1.894

5.  Synthesis of C-glycoside analogues of beta-galactosamine-(1-->4)-3-O-methyl-D-chiro-inositol and assay as activator of protein phosphatases PDHP and PP2Calpha.

Authors:  Sunej K Hans; Fatoumata Camara; Ahmad Altiti; Alejandro Martín-Montalvo; David L Brautigan; Douglas Heimark; Joseph Larner; Scott Grindrod; Milton L Brown; David R Mootoo
Journal:  Bioorg Med Chem       Date:  2010-01-04       Impact factor: 3.641

6.  Reciprocal control of pyruvate dehydrogenase kinase and phosphatase by inositol phosphoglycans. Dynamic state set by "push-pull" system.

Authors:  Patricia McLean; Sirilaksana Kunjara; A Leslie Greenbaum; Khalid Gumaa; Javier López-Prados; Manuel Martin-Lomas; Thomas W Rademacher
Journal:  J Biol Chem       Date:  2008-09-03       Impact factor: 5.157

Review 7.  Polycystic Ovary Syndrome: Insights into the Therapeutic Approach with Inositols.

Authors:  Maria A Sortino; Salvatore Salomone; Michele O Carruba; Filippo Drago
Journal:  Front Pharmacol       Date:  2017-06-08       Impact factor: 5.810

8.  Insulin-mimicking bioactivities of acylated inositol glycans in several mouse models of diabetes with or without obesity.

Authors:  Susumu Suzuki; Chitose Suzuki; Yoshinori Hinokio; Yasushi Ishigaki; Hideki Katagiri; Makoto Kanzaki; Viatcheslav N Azev; Nilanjana Chakraborty; Marc d'Alarcao
Journal:  PLoS One       Date:  2014-06-27       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.